Phase 1 trial of SION-109 oral therapy doses first volunteer
The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic fibrosis (CF), as announced by Sionna Therapeutics, the therapy’s developer. After receiving the green light from the U.S. Food and Drug Administration, the trial has enrolled healthy volunteers to…